Wendell Amy McBride sold $647K of AXGN
Wendell Amy McBride sold 13,353 shares of Axogen, Inc. (AXGN) at $48.42 ($0.65M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale by a director, executed under a pre-arranged Rule 10b5-1 plan, which typically limits interpretive value for company-specific news.
Market read
Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing without accompanying company news.
What to watch
The article provides no context on total planned sales, prior insider activity cadence, or whether the sale was part of a larger scheduled program beyond this single transaction.
Background
The article is a Form 4 insider transaction disclosure for Axogen, Inc. (AXGN).
Ticker impact
Axogen director Wendell Amy McBride sold 13,353 shares in an open-market transaction on 2026-08-11 under a 10b5-1 plan.
Low likelihood of a sustained price move driven solely by this Form 4 sale.
The filing is an insider transaction, not an earnings, guidance, deal, or regulatory event. The presence of a 10b5-1 plan reduces interpretive value for directional information.
Market effects
No clear sector read-through from a single director 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with periods of weaker outlook or liquidity needs, so traders may still watch for follow-on disclosures.
Key entities
- issuerAxogen, Inc.
US-listed company whose director insider sale is disclosed on Form 4.
- insiderWendell Amy McBride
Director who sold 13,353 shares at $48.4230 on 2026-08-11 under a 10b5-1 plan.
